ArticleBMC gastroenterology2025
Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with Ulcerative Colitis and Crohn's disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Evaluating the correlation between fecal and serum calprotectin in inflammatory bowel disease.Scientific reports · 2026Observational
- The aspiration of precision glucocorticoid pharmacotherapy in immune-mediated diseases: where do we stand in integrating pharmacogenomics and biomarkers for individualized treatment?Frontiers in immunology · 2026Review
- High Prevalence and Clinical Associations of Vitamin D Deficiency in Inflammatory Bowel Disease: Evidence from a Tertiary Center Cohort.Nutrients · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is an idiopathic disorder characterized by repeated relapses and remissions. Endoscopy, the gold standard for diagnosis and monitoring of these patients is time consuming, expensive, and invasive. Hence, faecal calprotectin (FCP) has been suggested as marker to determine the degree of intestinal inflammation and predict relapse in IBD.
objectiveTo use FCP as a predictor of clinical activity and endoscopic severity in IBD patients in a tertiary care hospital in Southern India.
methodsStudy subjects underwent clinical examination, endoscopy, blood tests and stool FCP. For Endoscopic activity simple endoscopic score for Crohn's disease (SES-CD) and Ulcerative Colitis endoscopic index of severity (UCEIS) scores were used, and clinical activity was assessed by Crohn's disease activity index (CDAI) and simple clinical colitis index (SCCAI) for CD and UC respectively. At six months, blood, and stool FCP test were repeated which were compared with endoscopic and clinical activity indices.
resultsThe number of males was higher in both CD (13/8) and UC (19/14). At first visit and follow up, CDAI and FCP were positively correlated (r-0.689, p- 0.016) (r- 0.425, p-value < 0.05). In CD, the sensitivity and specificity of FCP in detecting active disease and remission were 93.8% and 80% respectively (AUC-0.869). At follow up, the sensitivity and specificity were 80% and 93.3% respectively (AUC-0.867). In patients with UC, SCCAI score and FCP levels positively correlated (r-0.231/0.387, p-value 0.001/0.001) at both the first and follow up visits. The sensitivity of FCP in detecting UC in active and remission states was 92.6% whereas the specificity was 83.3%. AUC was 0.88. At the time of follow up, the sensitivity of FCP in detecting UC in active and remission states was 89.9% whereas the specificity was 87.0% and AUC was 0.879.
conclusionThis study confirmed that FCP level shows strong association with clinical and endoscopic activity indices in patients of IBD. Therefore, FCP levels could be used as a surrogate marker for monitoring mucosal status as well as predicting endoscopic remission in IBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.